<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Low-density blood cells from patients with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess of blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>) release a high molecular weight inhibitory substance that reduces the entry of <z:mpath ids='MPATH_458'>normal</z:mpath> progenitor cells of granulocytes and macrophages (CFU-GM) into the S-phase </plain></SENT>
<SENT sid="1" pm="."><plain>Out of 20 patients with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA and <z:mp ids='MP_0011356'>RAS</z:mp>) only 3 were positive </plain></SENT>
<SENT sid="2" pm="."><plain>One patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> was negative </plain></SENT>
<SENT sid="3" pm="."><plain>Serial examination of 3 patients (two RA and one <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) revealed that the production of the inhibitory activity preceded the development of the disease into <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>, or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>With one exception, the inhibitory activity in positive cases was neutralized by antiserum against human placental ferritin </plain></SENT>
</text></document>